NASDAQ : BRTX
BioRestorative Therapies, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.4003 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.78M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.85M |
| Enterprise Value | -1.71M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.27M |
| Shares Outstanding | 1.27M |
| Shares Change (YoY) | +38.49% |
| Shares Change (QoQ) | +81.89% |
| Owned by Insiders (%) | 3.24% |
| Owned by Institutions (%) | 15.00% |
| Float | 1.21M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.23 |
| Forward PS | 1.91 |
| PB Ratio | 0.59 |
| P/TBV Ratio | 0.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.35 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -241.14% |
| Return on Assets (ROA) | -118.81% |
| Return on Invested Capital (ROIC) | -193.30% |
| Return on Capital Employed (ROCE) | -470.16% |
| Weighted Average Cost of Capital (WACC) | 8.77% |
| Revenue Per Employee | $25,562 |
| Profits Per Employee | -$789,756 |
| Employee Count | 14 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.85 |
| 52-Week Price Change | -95.29% |
| 50-Day Moving Average | 2.45 |
| 200-Day Moving Average | 6.18 |
| Relative Strength Index (RSI) | 34.34 |
| Average Volume (20 Days) | 38,229 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 14,778 |
| Short Previous Month | 13,152 |
| Short % of Shares Out | 1.16% |
| Short % of Float | 1.22% |
| Short Ratio (days to cover) | 0.41 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 357,870 |
| Gross Profit | 329,550 |
| Operating Income | -14.23M |
| Pretax Income | -11.06M |
| Net Income | -11.06M |
| EBITDA | -14.01M |
| EBIT | -14.23M |
| Loss Per Share | -$19.51 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.59M |
| Total Debt | 28,774 |
| Net Cash | 3.56M |
| Net Cash Per Share | $2.80 |
| Equity (Book Value) | 3.03M |
| Book Value Per Share | 2.38 |
| Working Capital | 2.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -11.82M |
| Capital Expenditures | -79,669 |
| Depreciation & Amortization | 210,598 |
| Net Borrowing | n/a |
| Free Cash Flow | -11.90M |
| FCF Per Share | -$9.34 |
Margins
| Measure | Value |
|---|
| Gross Margin | 92.09% |
| Operating Margin | -3,975.00% |
| Pretax Margin | -3,089.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.49% |
| Shareholder Yield | -38.49% |
| Earnings Yield | -1,340.71% |
| FCF Yield | -635.30% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 90.84% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 8, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -57.29 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |